Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. [electronic resource]
Producer: 20040617Description: 3271-7 p. digitalISSN:- 0006-4971
- Adult
- Aged
- Aged, 80 and over
- Alkyl and Aryl Transferases -- antagonists & inhibitors
- Carrier Proteins -- metabolism
- Cell Survival -- drug effects
- DNA-Binding Proteins -- metabolism
- Disease Progression
- Farnesyltranstransferase
- Female
- HSP40 Heat-Shock Proteins
- Heat-Shock Proteins -- metabolism
- Humans
- Male
- Middle Aged
- Mitogen-Activated Protein Kinase 1 -- metabolism
- Mitogen-Activated Protein Kinase 3
- Mitogen-Activated Protein Kinases -- metabolism
- Multiple Myeloma -- complications
- Phosphorylation -- drug effects
- Protein Prenylation -- drug effects
- Protein Serine-Threonine Kinases
- Proto-Oncogene Proteins -- metabolism
- Proto-Oncogene Proteins c-akt
- Quinolones -- administration & dosage
- STAT3 Transcription Factor
- Salvage Therapy
- Signal Transduction -- drug effects
- Trans-Activators -- metabolism
- ras Proteins -- metabolism
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.